Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Ali, Meser M ^a   Janic, Branislava ^a   Babajani Feremi, Abbas ^a   Varma, Nadimpalli R S ^a   Iskander, A S M ^a   Anagli, John ^a   Arbab, Ali S ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; GADOLINIUM PENTETATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1; TECHNETIUM 99M; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; ANGIOGENESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROVASCULATURE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA VOLUME; PROTEIN EXPRESSION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CAPILLARY PERMEABILITY; DRUG EFFECT; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; VASCULARIZATION;

ANIMALIA; RATTUS;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; GLIOMA; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 77649333248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008727     Document Type: Article

References (51)

1. Remer S, Murphy ME (2004) The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin J Oncol Nurs 8: 368-376.
2. Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, et al. (2005) [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma]. Bull Cancer 92: 333-342.
3. Los M, Roodhart JM, Voest EE (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450.
4. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, et al. (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
5. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7: 1152-1160.
6. Dietrich J, Norden AD, Wen PY (2008) Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 21: 736-744.
7. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, et al. (2004) PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55: 426-432; discussion 432.
8. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, et al. (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16: 225-230.
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
10. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, et al. (2003) MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 30: 448-455.
11. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
12. Bicknell R, Lewis CE, Ferrara N (1997) The role of vascular endothelial growth factor in the regulation of blood vessel growth in Tumor Angiogenesis. pp 185-199.
13. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, et al. (1998) Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49-58.
14. Fong TA, Shawver LK, Sun L, Tang C, App H, et al. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/ KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106.
15. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, et al. (2000) PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189.
16. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
17. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
18. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, et al. (1999) MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10: 903-907.
19. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, et al. (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10: 260-266.
20. Cheng HL, Wallis C, Shou Z, Farhat WA (2007) Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrastenhanced MRI using contrast agents of different molecular weights. J Magn Reson Imaging 25: 137-145.
21. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, et al. (2008) Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 247: 391-399.
22. Blankenberg FG, Backer MV, Levashova Z, Patel V, Backer JM (2006) In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33: 841-848.
23. Levashova Z, Backer M, Backer JM, Blankenberg FG (2008) Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjug Chem 19: 1049-1054.
24. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, et al. (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with singlechain VEGF-based probes. Nat Med 13: 504-509.
25. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, et al. (2002) PTK787/ ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022.
26. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, et al. (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11: 4934-4940.
27. Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, et al. (2008) Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J 22: 3234-3246.
28. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, et al. (2005) Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrastenhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11: 5827-5832.
29. Salmon BA, Salmon HW, Siemann DW (2007) Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer 43: 1622-1629.
30. Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K (2007) The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo 21: 721-728.
31. Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y (2003) MR imagingguided focused US ablation of breast cancer: histopathologic assessment of effectiveness- initial experience. Radiology 227: 849-855.
32. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, et al. (2006) Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 57: 761-771.
33. Semple SI, Staff RT, Heys SD, Redpath TW, Welch AE, et al. (2006) Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17: 1393-1398.
34. Mussurakis S, Buckley DL, Horsman A (1997) Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors. Br J Radiol 70: 446-451.
35. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, et al. (1998) Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 171: 941-949.
36. Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, et al. (2004) MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20: 865-873.
37. Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20: 652-661.
38. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, et al. (2006) Cytokinemediated deployment of SDF-1 induces revascularization through recruitment of CXCR4(+) hemangiocytes. Nat Med 12: 557-567. Epub 2006 Apr 2030.
39. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE (2007) The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 56: 1817-1826.
40. Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, et al. (2009) SPECT and PET Imaging of EGF Receptors with Site-Specifically Labeled EGF and Dimeric EGF. Bioconjug Chem.
41. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, et al. (1987) Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 22: 665-671.
42. Marzola P, Farace P, Calderan L, Crescimanno C, Lunati E, et al. (2003) In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. Int J Cancer 104: 462-468.
43. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, et al. (2003) Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9: 355-362.
44. Wang Z, Su MY, Najafi A, Nalcioglu O (2001) Effect of vasodilator hydralazine on tumor microvascular random flow and blood volume as measured by intravoxel incoherent motion (IVIM) weighted MRI in conjunction with Gd-DTPA-Albumin enhanced MRI. Magn Reson Imaging 19: 1063-1072.
45. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC (1993) Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 29: 616-622.
46. van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, et al. (1996) Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 198: 813-818.
47. Ewing JR, Brown SL, Lu M, Panda S, Ding G, et al. (2006) Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 26: 310-320.
48. Ewing JR, Knight RA, Nagaraja TN, Yee JS, Nagesh V, et al. (2003) Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med 50: 283-292.
49. Barboriak DP, MacFall JR, Viglianti BL, Dewhirst Dvm MW (2008) Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging 27: 1388-1398.
50. Barboriak DP, Padua AO, York GE, Macfall JR (2005) Creation of DICOM-aware applications using ImageJ. J Digit Imaging 18: 91-99.
51. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, et al. (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31: 2022-2028.